BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Year-over-year net income growth rate
| Period | Value |
|---|---|
| Q4 2025 | 1805.92% |
| Q3 2025 | 153.67% |
| Q2 2025 | 15790.63% |
| Q1 2025 | 100.12% |
| Q4 2024 | -90.94% |
| Q3 2024 | -10.72% |
| Q2 2024 | 64.18% |
| Q1 2024 | 42.69% |
| Q4 2023 | -70.77% |
| Q3 2023 | 52.01% |
| Q2 2023 | -41.24% |
| Q1 2023 | 25.45% |
| Q4 2022 | -68.25% |
| Q3 2022 | 27.76% |
| Q2 2022 | 20.67% |
| Q1 2022 | -317.32% |
| Q4 2021 | 69.76% |
| Q3 2021 | -36.12% |
| Q2 2021 | 32.80% |
| Q1 2021 | -6.27% |
| Q4 2020 | -31.18% |
| Q3 2020 | -19.45% |
| Q2 2020 | -2.68% |
| Q1 2020 | -1333.98% |
| Q4 2019 | 93.03% |
| Q3 2019 | 0.10% |
| Q2 2019 | -21.17% |
| Q1 2019 | -13.20% |
| Q4 2018 | 7.31% |
| Q3 2018 | -60.45% |
| Q2 2018 | 28.44% |
| Q1 2018 | -31.90% |
| Q4 2017 | -29.13% |
| Q3 2017 | 10.38% |
| Q2 2017 | -18.76% |
| Q1 2017 | -215.77% |
| Q4 2016 | 60.94% |
| Q3 2016 | 29.19% |
| Q2 2016 | 28.69% |
| Q1 2016 | -25.90% |